The Lisaiceland offering is now closed and is no longer accepting investments.

Lisaiceland

ClinicalTrials360

Small OPO
Katy, TX
Biotechnology
Accepting International Investment
Play video

Bringing Innovative Disruption with ClinicalTrials360

Invest in Lisaiceland

We've been doing product R&D and clinical projects consulting since 2013. Our successes have been in birthing fresh ideas, innovative designs and highly-scalable deployments for our blockchained healthcare-AI-powered platform (SaaS)  ClinicalTrials360 . It's based on and powered by our general-purpose AI platform myai.expert. 


This project is in honor of all our healthcare caregivers worldwide. We were founded as a boutique, responsive, pro-active, diversity-inclusive and responsible research and development shop. We've worked for the largest healthcare and other industry established players and companies and have honed our development, product and services and marketing deliveries and business administration skills.

End-to-End Clinical Trials Data Management

It started from a whiteboard idea for a post-grad project late 2012 and early 2013 and took off in earnest by summer 2013.


We then evolved into a major set of clinical pipeline workflows, apps, databases, IoT, automations (RPA), e-Learning, e-certifications, SaaS, APIs and clinical consulting. Finally, to an integrated platform with AI, blockchain and many other awesome technologies and fully-developed , tested and deployed techstacks! 


We Release ONLY When Fully Ready - No Vaporware

We didn't want to file for our first OPO until we had a SOLID working, stable product and at least two solid years of earnings that paid our bills at our Lisaiceland venue (Texas DBA) from doing clinical consulting work. This is how we paid the development bills. Raw hard work and some conservative bootstrapped financial smarts.


The Release Candidate 0 (or RC0) for user acceptance testing (UAT) started in earnest on February 01, 2018.

Our Evolution

  • 2013 -- DONE -- Turn Post-grad project idea into a running viable project
  • 2013 -- DONE -- Create a dedicated team in place and work the project
  • 2013 - 2015 -- DONE -- Delivered alpha proofs-of-concept (PoC)
  • 2016 - 2017 -- DONE -- Plus doing clinical consulting work using our apps to prove product, workflow and tweak everything till then and pay our bills 
  • 2017 -- DONE --Delivered solid betas
  • 2018 -- DONE -- Delivered a stable release candidate (RC0)
  • 2018 --  DONE -- Once the RC0 is out, register the DBA as a Delaware Public Benefits Corporation (PBC).
  • 2018+ --  WORK-IN-PROGRESS -- Then build this project out over the next five years for a hungry waiting market that wants a truly innovative democratized (i.e. meaning available to everyone at the lowest common price/benefits ratio) Clinical Trials Data Management solution that works for them at the cheapest price and no missing features in the workflow! Also register all our trademarks with USPTO.

Today our platform (SaaS - software as a service) exists in its first major Release Candidate (RC) RC0 as a highly-scalable SaaS bringing together:


  • A true Electronic Data Capture (EDC) system in its fullest form 
  • Deep Healthcare domain knowledge access at all points of entry/exit
  • Deep domain knowledge in clinical trials data management
  • LMS gamified-integrated e-Learning integration for learning, certification and completions
  • AI machine and deep-learning and blockchain integrated
  • Robotic process automation (RPA)
  • Highly-scalable infrastructure secure-cloud-based backbone
  • Apps, APIs, internet-of-things (IoT)
  • ...and so much more! 

The platform has already gone through nearly four plus years of solid R and D and testing in the Contract Research Organization healthcare specialty area (CRO - i.e. organization that does clinical trials for drug and medical devices sponsor companies).


We wanted to make a difference in solving MAJOR pain-points, one being research that does not end up in practice.

The Offering

Investment
$0.19 per share For Common Stock

When you invest you are betting the company’s future value will 

exceed $18.3M.


Perks*

$500+ — If you invest $500 or more, you will receive access to key private sneak peaks for all releases prior to release. PLUS you will receive a $50 cash gift card. PLUS all stock purchases has a 10% discount attached to it.

$5,000+ — If you invest $5,000 or more, you will receive access to key private sneak peaks for all releases prior to release. PLUS you will receive a $200 cash gift card. PLUS all stock purchases has a 10% discount attached to it.

$10,000+ — If you invest $10,000, you will receive access to key private sneak peaks for all releases prior to release. PLUS you will receive a $300 cash gift card. PLUS all stock purchases has a 10% discount attached to it.

*All perks occur after the offering campaign is completed


"Better 360°-Managed LIVE Clinical Trials Collectively Save More Lives"

What Have We Accomplished So Far

We have developed ClinicalTrials360 powered by our general-purpose AI-platform myai.expert, a blockchain-secured, AI-based platform (SaaS). It is out in solid beta release candidate trials right now as of February 01, 2018. It's built to handle massive amounts of HIPAA and GCP-secured Healthcare data for AI-based data-analytics and extraction of hidden clinical insights. More specifically, data for Clinical Trials Data Management (CTDM). This includes actual trials data and we're developing the next round of products to allow the initial pathology and therapeutics-based data analytics that will be consumed by our AI engine to generate significant insights and allowing the reduction of targets-choosing by PIs (Principal Investigators, i.e. Doctors, Medical Researchers, Chief RNs). We forecast that this reduction will be from six years average currently to under one year. We are in a race to achieve this over the next 1-3 years maximum with a production version integrated into our CTDM.


The uses for both ClinicalTrials360 and general AI platform myai.expert are way beyond this and has a very bright future!


Please Note: Clinical Trials refers to human-based trials of drug-therapies and/or medical devices. Combinations of these are also possible in any Clinical Trials.


We are doing more major iterations in 2018 and beyond to make it a unique offering solving challenges in Clinical Trials Data Management, incorporating full clinical data management (CDM) workflow, AI machine and deep-learning, e-Learning and e-Certifications and secured by our own private blockchain. We have implemented innovative design ideas to make the platform very easily-tweakable (by our development team and users) and highly scalable and operating in the cloud.

Historical Numbers So Far:

Lisaiceland® (unincorporated)

Texas DBA

Clinical Trials Consulting Completed successfully for 

2016 and 2017


2016 

CLINICAL TRIALS MANAGEMENT CONSULTING

USING WORKING POC

Revenue = $78,196


2017 

CLINICAL TRIALS MANAGEMENT CONSULTING

USING WORKING POC

Revenue = $73,060

Billions of Dollars and Time Wasted

Let's Do All We Can To Help Save!

Each year Billions are spent researching clinical treatments, but a staggering 85% of all research ends up not being put into practice – much of it passed over for reasons that could be avoided. Even when research findings are taken up by clinicians and those in charge of health policy, the average delay between publication and practice is 17 years.  (See Here)


Our Internal Active-Measures (Company Administration Model)

We've kept our costs, payroll and expenses to a minimum and have completed the first stable release candidate (RC) iteration for our platform. We're very practical and produce real products and services at all times. Zero-hype. All results. Our past performance, products and current iterations speak for themselves. We aim to deliver WORKING products and services of the highest quality.


We aim to maximize our expenditures in marketing our platform and maximize our profits. All current teammates are remote and on contract probation until the company achieves at least $5M in funding, revenue or a combination of both by Q4 2018.

Clinical Trials Data Management (CTDM)

Our focus is making all phases of clinical trials more efficient: design, actively running with PIs (principal investigators) and the full 360-degrees coverage of studies' and sites' operations, onsite-training, e-Learning, consulting and full clinical data management to final delivery.

 

Our efforts encompass working with other expert CROs, CRAs, CRCs, CDMs, PIs and bio pharmaceutical and medical device development sponsors.

Healthcare: CTDM Use-Case

Black & White

Why would you need or even desire more efficient clinical trials data management (CTDM) run on our platform? Plus, all this with related results for design, planning, setup, reporting, auditing, analytics, tracking and patient supervision - before, during and way after a trial is over?


Short Answer

Better 360°-Managed LIVE Clinical Trials (Data Management) and Much Better Final Workflows.


Collectively

Save More Lives. Period.

Our Platform

1 - 2 - 3 - START

Easiest System for Clinical Trials

1

Study Signup

aiSuperStudy

Get Secure Workspace

2

Login

Enter Your

Study Data

3

Manage

Your CDM

Workflow + Users

START

What Makes Our Platform Different

6 Problems Worth Solving

Problem 1: Costs

The number of clinical trials has doubled from 2011 to 2018 (March 25).

ClinicalTrials.gov currently lists 269,430 studies with locations in all 50 States and in 203 countries. (See Here)


Typical Clinical Trials Costs: See Here


Total costs for each of the therapeutic areas included in our model by clinical trial phase (assuming one trial per phase and not inclusive of failures):

Phase 1

Immunomodulation per-study costs ($6.6 million) are the highest in Phase 1 with costs of studies in ophthalmology ($5.3 million) and respiratory system ($5.2 million) ranking second and third, respectively. 

Phase 2

Hematology trial costs ($19.6 million) rank first, followed by pain and anesthesia ($17.0 million) and immunomodulation ($16.0 million). 

Phase 3

The most costly studies are in pain and anesthesia ($52.9 million) with studies in ophthalmology ($30.7 million) and cardiovascular ($25.2) area ranking second and third, respectively. 

Phase 4

 Respiratory system trial costs ($72.9 million) rank first, followed by oncology ($38.9 million) and pain and anesthesia ($32.1 million) study costs. 


Overall, the therapeutic area with the highest clinical research burden across all phases is respiratory system ($115.3 million) followed by pain and anesthesia ($105.4 million) and oncology ($78.6 million) trials (see Figure 3). On the other hand, trials in central nervous system, dermatology, and genitourinary system tend to cost the least overall. (see: https://goo.gl/osfV1H)


What's worse is that this cost is increasing rapidly. 

More than $7 of every $10 dollars is spent on administrative staff, clinical procedures, site monitoring and site retention. 

(see: https://goo.gl/NMycDL)


Great data management using our CTDM (aiSuperStudy + aiCTDM) system can drastically reduce that, reduce errors and become an integral part of a futuristic and highly-scalable system that not solves current clinical data management pain-points but also has AI insights and blockchain security as added (huge) benefits.


We have taken aim squarely to make trials workflows more efficient so that the above IMMENSE costs can be lowered. That's the first order of the day.


Problem 2: Design

Designing and running successfully a Clinical Trial workflow (aka pipeline) is a tough job and it requires significant amount of data:

 

To determine which method or strategy is going to be the best for the drug at hand. It is a very people-intensive activity and contrary to popular understanding for clinical trials and healthcare in general, it is NOT a technology-intensive domain.


Problem 3: Setup

The setup of a Clinical Trial involves a lot of things:

 

Recruitment of test subjects, administration, reporting, compliance, etc. The usage of data and technology, specifically AI machine and deep learning and e-learning, e-certifications and e-completions (i.e. actually running the trials) for better predictability of outcomes and generation of actionable-insights is critical in this step and deploying a conventional setup is not possible anymore. 


Problem 4: Tracking & Monitoring

This is one of the biggest problems Clinical Trial Teams face:

 

Tracking the dosage and reactions of their trial patients. Even though phone calls, clinic visits and even video documentation helps, it doesn't really solve the problem significantly. 


Problem 5: Reporting

One of the biggest problems in clinical trials is reporting. 

Representation of data, results, conclusions and then extracting the results from that data, all of this affects the efficacy and efficiency of the trials themselves and may even lead to inefficient data for future research and ongoing work as well. (See Here)


Problem 6: Auditing

How does one verify the trial results?

 

Who was responsible for which step? Auditing in a nightmare for any business or process, but auditing a Clinical Trial that is responsible for the lives of people is a whole different ball game. 

We Have the Solutions

Lisaiceland Has Developed a Groundbreaking Solution

We believe that Better CTDM results lead to better implementations driving down key cost drivers for newer innovative therapies and drugs.

The increasing cost of clinical research has significant implications for public health, as it affects drug companies' willingness to undertake clinical trials, which in turn limits patient access to novel treatments. (See Here)


The cost of failed clinical trials is very high. Estimates vary on the cost of a failed clinical trial, but figures range anywhere from $800 million to $1.4 billion 

(See Here)


Hence, we have created a blockchain plus AI-powered SaaS that helps CROs, users, admins, researchers and patients across the world conduct efficient, cost-effective and easy to manage Clinical Trials. 

Our Solution

  • A one-stop SaaS (aka platform or system) 
  • It's setup to be operational for CROs that's set up for optimal performance
  • Smart e-Learning
  • Smart e-Certification
  • Smart e-Completions 
  • Smart AI-based platform to plan, design, setup, track, analyze and supervise the trials
  • Based on Machine Learning and Deep Learning, the platform grows more intelligent with the passage of time and help the researchers make informed decisions. 
  • Targeting reducing the pathology and therapeutics-based analytics for human organ site-targets-selections from 6 to 1 year
  • Secured by the best private blockchain available
  • A fully-Integrated EHR / EMR Hospital Management System to reduce errors for double-entry of patient data

What Makes Lisaiceland Unique?

  • INTEGRATED Smarter Clinical Trials
    • Smart e-Learning
    • Smart e-Certification
    • Smart e-Completions
  • INTEGRATED Localized, including RTL support, in 56+ Languages
  • INTEGRATED Cloud-Based Blockchained Healthcare-AI Platform 
  • INTEGRATED SERVERLESS Apps and APIs on Scalable AWS
  • INTEGRATED Highly-Scalable: Millions of Transactions No Latency
  • INTEGRATED Private Blockchain-Secured (genesis block on AWS)
  • INTEGRATED LIVE Clinical Trials Studies Completions: Plan, Design, Track, Monitor, Audit, Analyze, report and Maintain and much more!
  • INTEGRATED Immersive Workflow eLearning
  • INTEGRATED Immersive Workflow eCertification
  • INTEGRATED Immersive Workflow eCompletion
  • INTEGRATED Immersive Workflow Gamification
  • INTEGRATED Fully Open-Exchange Data Formats
  • INTEGRATED 50-Languages Localization
  • INTEGRATED Remote Patient-Monitoring (aiSitenCam® and aiPat®)
  • INTEGRATED Industrial-Grade Robotic Process Automation (RPA)
  • INTEGRATED IoT Runs on ALL Major HW and SW Platforms
  • INTEGRATED AI Core (Machine and Deep-Learning)
  • INTEGRATED Voice-Prompted-Based 2-Way NLP/NLU Chatbot
  • INTEGRATED Risk-Based Workflow Processing
  • INTEGRATED Collaborative Analytics Charts & Dashboards
  • INTEGRATED CTDM Using Best CDM Methods, eCRF, EDC, eTMF
  • INTEGRATED 100% HIPAA, ICH-GCP, ISO, DIA and Other Compliances
  • INTEGRATED Highly Scalable and Secure Digital DRM and AWS Serverless Backbone Technologies Allowing Deployments Everywhere Literally (Internet/wifi off/on)
  • INTEGRATED LIVE Reporting, Auditing, Compliance & Approvals
  • INTEGRATED LIVE Post-Trial Monitoring
  • INTEGRATED Extra-Large Workflow Screens - Easiest For All Users
  • INTEGRATED LIVE Usage, Tutorials, Info Docs Available Easily
  • INTEGRATED LIVE Integrated ChatBot LIVE 24/7/365 Support
  • INTEGRATED LIVE Integrated 24/7/365 LIVE Support (except holidays)
  • GUARANTEED Lowest Globally-Competitive Pricing
  • Many More Apps, Modules and Features coming soon!

Our Market and Industry

Problems We See as Developers and Workflow Integrators

The current state for a single clinical trials data management "system-of-record" that's powered by an Blockchained-AI platform is:

  • In general healthcare terms and specifically for three areas of healthcare (e.g. LIVE electronic health record (EHR), clinical trials data management (aka CTDM of which EDC is a small part, see market size for EDC) for: CDM, EHR, MRI, Oncology scan-analytics) with accompanying AI platforms, apps, APIs & automations are a daunting & confusing mixed bag of systems and platforms.
  • They're coded and deployed with really old legacy coding and deployment paradigms that do NOT scale well, with apps, APIs & confusing ideas.
  • We're not even going to mention legacy systems "integrations."
  • Any and all types of LIVE trials management & research is, has been & becomes very complex really fast. 
  • The increasing cost of clinical research, in general, has significant implications for public health, as it affects drug companies' willingness to undertake clinical trials, which in turn limits patient access to novel treatments (See Here). In our opinion, that's a big problem that the private and public sectors needs to team up and we have built a solution that address that from an increasing in efficiencies in data analytics, inputs and other innovative features to address this.
  • By the way...we believe in making a great core CTDM with a core EDC (see more of what we consider to be great features)


Specific Problematic Areas Ready for Disruption

  • AI-Based Smart Integrated Deeply Domain-Knowledgeable Natural 2-Way Voice Assistants
  • AI-Based LIVE Integrated Electronic Health Record (EHR) Multi-Hospital Systems
  • AI-Based LIVE Integrated Trials Management for Clinical Trials In General (CTDM)
  • AI-Based LIVE Integrated MRI-Based LIVE Trials Management (MRI)
  • AI-Based LIVE Integrated Oncology-Based LIVE Trials Management (Onco)
  • AI-Based LIVE Integrated Additional myClinApps

Significant Market Findings

  • 2016: The global clinical trials market witnessed a lucrative growth in 2016 and is expected to grow at a CAGR of over 5.5% from 
  • 2017 to 2025: The market is expected to be dominated by Phase III as of 2016, with Phase I anticipated to witness the fastest growth

  • Increasing innovation and evolution of treatment is predicted to contribute towards growth of the expanded access trials segment

  • Oncology: Based on indication, the oncology segment is anticipated to witness the fastest growth. 

  • Preclinical, Oncology-Focused: According to various sources, more than USD $38.0 billion is currently being spent by the healthcare industry towards preclinical and clinical development of oncology therapy products

  • North America #1 Market: North America dominated the overall market in terms of revenue share in 2015 owing to the presence of big outsourcing firms and increasing R&D in the region.

  • Key players: Quintiles IMS, Paraxel International Corporation, Charles River Laboratories, ICON plc, SGS SA among the others dominate the global clinical trials market while (note: this is representing maximum volume in 2016)

Source

Another More Detailed Report Here: 

Clinical Trials Market Analysis By Phase (Phase I/II/III/IV), By Study Design (Interventional, Observational, Expanded Access), By Indication (Autoimmune, Pain management, Oncology, CNS condition, Diabetes, Obesity), And Segment Forecasts, 2014 - 2025

Our Main Reference Data-Points Considered:

U.S. clinical trials market, by phase, 2014 - 2025 (USD Billion)

Source

(for above, please see: https://clinicaltrials.gov/ct2/resources/trends)

Hello From All Of Us!

We Strive To Be Publicly-Responsible and Transparent

In the Press

Lisaiceland Inc.® Launches New Version Of myai.expert® ClinicalTrials360®
February 12, 2018

Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.

LISAICELAND INC.® LAUNCHES NEW VERSION OF MYAI.EXPERT® CLINICALTRIALS360®
February 12, 2018

Lisaiceland Inc.® is proud to announce the release of the latest iteration of myai.expert® ClinicalTrials360® platform! It is a full Blockchained Democratized Healthcare-AI SaaS. The new release is called Release Candidate (RC) Zero or RC0.

Lisaiceland Inc.® Launches New Version Of myai.expert® ClinicalTrials360®
February 12, 2018

Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.

Lisaiceland Inc.® Launches New Version Of myai.expert® ClinicalTrials360®
February 12, 2018

Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.

Lisaiceland Inc.® Launches New Version Of myai.expert® ClinicalTrials360®
February 12, 2018

Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.

Lisaiceland Inc.® Launches New Version Of myai.expert® ClinicalTrials360®
February 12, 2018

Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.

Lisaiceland Inc.® Launches New Version Of myai.expert® ClinicalTrials360®
February 12, 2018

Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.

Lisaiceland Inc.® Launches New Version Of myai.expert® ClinicalTrials360®
February 12, 2018

Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.

Lisaiceland Inc.® Launches New Version Of myai.expert® ClinicalTrials360®
February 12, 2018

Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.

Lisaiceland Inc.® Launches New Version Of myai.expert® ClinicalTrials360®
February 12, 2018

Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.

Lisaiceland Inc.® Launches New Version Of myai.expert® ClinicalTrials360®
February 12, 2018

Katy, Texas, 02/06/2018 — We're excited at Lisaiceland® to announce the release of the latest iteration of myai.expert® ClinicalTrails360®! The new release is called Release Candidate (RC) Zero or RC0.

Offering Summary

Maximum [563,157] shares of common stock ($106,999.83)

Minimum [52,631] shares of common stock ($9,999.89)


Company
Lisaiceland Inc.
 

Corporate Address
Mailing Address:
Lisaiceland Inc.
C/O: Lisa Kristinardottir
22136 Westheimer Parkway,
Katy, Texas, 77450
 

Description of Business
Blockchained Democratized
Healthcare-AI Platform (SaaS)

with
Integrated Healthcare CRO 
and Staffing Services
 

Type of Security Offered
 Common Stock
 
Purchase Price of Security Offered
$0.19 / Per Share
 

Minimum Investment Amount (per investor) 
Minimum $499.89















Perks

$500+ — If you invest $500 or more, you will receive access to key private sneak peaks for all releases prior to release. PLUS you will receive a $50 cash gift card. PLUS all stock purchases has a 10% discount attached to it.

$5,000+ — If you invest $5,000 or more, you will receive access to key private sneak peaks for all releases prior to release. PLUS you will receive a $200 cash gift card. PLUS all stock purchases has a 10% discount attached to it.

$10,000+ — If you invest $10,000, you will receive access to key private sneak peaks for all releases prior to release. PLUS you will receive a $300 cash gift card. PLUS all stock purchases has a 10% discount attached to it.

*All perks occur after the offering is completed

Irregular Use of Proceeds

The Company has no plans to incur any irregular use of proceeds.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$11,143.00 USD
$7,983.00 USD
Cash And Cash Equivalents
$4,364.00 USD
$7,983.00 USD
Accounts Receivable
$6,779.00 USD
$0.00 USD
Short Term Debt
$1,656.00 USD
$4,397.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$73,060.00 USD
$78,196.00 USD
Costs Of Goods Sold
$66,118.00 USD
$74,095.00 USD
Taxes Paid
$1,041.00 USD
$615.00 USD
Net Income
$5,901.00 USD
$3,486.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Follow Lisaiceland to get notified of future updates!

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Show More Comments